The EU Clinical Trials Regulation 536/2014 significantly expanded the transparency requirements for clinical trials in the EU, resulting in the public availability of most documents and information submitted by sponsors to the new EU Clinical Trial Information System. Tune into this episode of Covington’s Life Sciences Audiocast, where Robin
Continue Reading EU Talking Life Sciences Audiocast: Clinical Trial Transparency Requirements in the EU
Roderick Dirkzwager
Roderick Dirkzwager advises clients in the life sciences sector on a broad range of regulatory, transactional and intellectual property matters relating to the discovery, development and commercialization of their products.
Roderick is a member of Covington’s Diversity and Inclusion Committee and is a co-lead of the LGBT+ Affinity Group in London.
With a broad life sciences practice, Roderick regularly advises on:
EU, Irish, and UK regulatory issues relating to pharmaceutical products and medical devices;
commercial agreements that span the product life-cycle in the life sciences sector, including collaborations and other strategic agreements, clinical trial agreements, distribution arrangements and manufacturing and supply contracts;
regulatory and commercial due diligence for life sciences transactions; and
intellectual property issues arising in corporate transactions and IP-related contracts.
Roderick is also a member of Covington's Life Sciences in Africa team and advises clients on regulatory and commercial strategies for the supply of medical products across Africa, including through international recognition procedures such as WHO pre-qualification. Prior to joining the firm, Roderick completed his Ph.D. in Biochemistry, focusing on the development of novel, low-cost malaria diagnostic technologies using DNA aptamers.
EU Pharma Legislation Review Series: Unitary Supplementary Protection Certificates and Recast
On April 27, 2023 the European Commission (“Commission”) released its proposal to introduce a single procedure for the granting of Supplementary Protection Certificates (“SPCs”) throughout the EU. The changes are intended to complement the new unitary patent procedure that will enter into force on June 1, 2023. The Commission intends…
Continue Reading EU Pharma Legislation Review Series: Unitary Supplementary Protection Certificates and Recast
EU Pharma Legislation Review Series: Bolar Exemption under Patent Rights
The latest draft pharmaceutical legislation published by the European Commission (“Commission”) is set to shake up the regulatory exclusivity protections available to innovator pharmaceutical companies operating in the EU (as discussed in further in our previous blog). As part of these developments, the Commission has clarified the…
Continue Reading EU Pharma Legislation Review Series: Bolar Exemption under Patent Rights
EU Pharma Legislation Review Series: Access to Documents and Transparency of R&D Funding
The EU’s latest draft pharmaceutical legislation contains some interesting developments on transparency matters, both in relation to access to documents and transparency around the funding of research and development of medicinal products.
1. Draft Regulation – Further Clarity Regarding Public Access to Documents
Disclosure of documents in response to an…
Continue Reading EU Pharma Legislation Review Series: Access to Documents and Transparency of R&D FundingEU Pharma Legislation Review Series: AMR and Transferable Exclusivity Vouchers

The European Commission has proposed specific measures to increase the supervision and monitoring of the use of antimicrobial medicinal products (or “antimicrobials”), with the aim to counter the spread of antimicrobial resistance (“AMR”). At the same time, the measures are also aimed at promoting and incentivizing the development of new…
Continue Reading EU Pharma Legislation Review Series: AMR and Transferable Exclusivity Vouchers
EU Pharma Legislation Review Series: The Regulatory Sandbox – A Safe Space for Innovators to Grow
As part of its policy goal of promoting innovation, the Commission’s proposed Regulation creates the concept of a “regulatory sandbox.” If the concept survives the legislative process, the sandbox will be a structured, regulated and time-limited environment in which innovative technologies, products, services or approaches might be tested in a…
Continue Reading EU Pharma Legislation Review Series: The Regulatory Sandbox – A Safe Space for Innovators to Grow
EU Pharma Legislation Review Series: Orphan Medicines
On 26 April 2023, the European Commission published its long awaited proposal to revise the EU pharmaceutical legislation. The proposal includes a new draft Regulation, which will repeal Regulation (EC) No 726/2004, the Orphan Medicines Regulation 141/2000 and the Paediatric Regulation 1901/2006.
As expected, the draft Regulation significantly shakes…
Continue Reading EU Pharma Legislation Review Series: Orphan Medicines
EU Pharma Legislation Review Series: Regulatory Data Protection
The European Commission (“Commission”) intends to change the rules on regulatory data protection (“RDP”) of medicinal products. The Commission stated in its Impact Assessment for the revised pharmaceutical legislation that it wants to strike a balance between “providing attractive incentives for innovation and supporting timely patient access to medicinal…
Continue Reading EU Pharma Legislation Review Series: Regulatory Data ProtectionUK MHRA to recognize foreign regulatory approvals for medicines and medical technologies and promote digital innovation
Last week, Jeremy Hunt, Chancellor of the Exchequer, published his Spring Budget for the UK. It identified life sciences and digital technologies as “high growth sectors,” which the UK Government wishes to prioritize. Among other things, the Budget outlined the Government’s plans to simplify medicines and technology approvals…
Continue Reading UK MHRA to recognize foreign regulatory approvals for medicines and medical technologies and promote digital innovation
New Guidance on the Application of Article 97 of the MDR to Legacy Devices Certified under the MDD or AIMDD
It’s all happening in the device space. Further to the European Commission’s meeting we discussed last week on the proposed three-year extension to the transition period under the Medical Devices Regulation (EU) 2017/745 (MDR), the EU Medical Device Coordination Group (MDCG) has now published guidance clarifying the use of the non-compliance procedure under Article 97 of the MDR.
Under Article 97, competent authorities can temporarily allow devices that do not comply with the MDR to continue to be placed on the market if they do not present an unacceptable risk to the health or safety of individuals or to public health.Continue Reading New Guidance on the Application of Article 97 of the MDR to Legacy Devices Certified under the MDD or AIMDD